Protyon is coordinating the €1.8 million DELPHI project, a collaboration between the University of Groningen, UMCG, Protyon, and Health-Ecore, aimed at advancing personalized oncology. This funding has been awarded by the Samenwerkingsverband Noord-Nederland (SNN) – Just Transition Fund (JTF).
The DELPHI project seeks to revolutionise lung cancer treatment through cutting-edge molecular modeling and computational analysis. Building on established collaborations between UMCG, the University of Groningen, and two regional SMEs, namely, Health-Ecore and Protyon, the initiative aims to deliver personalised treatment recommendations by utilising molecular fingerprints and advanced tools to create detailed 3D models of cancer-driving proteins in patients.
Lung cancer remains the most common type of cancer globally and the leading cause of cancer-related mortality, with approximately 2 million new diagnoses and 1.8 million deaths annually. Europe and North America, in particular, face a high prevalence of this disease, making it the most frequently diagnosed cancer among both men and women. In the Netherlands, lung cancer ranks among the top causes of cancer-related deaths, with about 13,000 new cases diagnosed each year.
Protyon is pioneering advancements in personalized medicine by harnessing molecular modeling to address the challenges of non-small cell lung cancer (NSCLC) among others. Through this innovative approach, Protyon aims to deliver patient-specific treatment strategies that not only improve outcomes but also drive down healthcare costs by fostering collaboration and cutting-edge solutions.
The consortium is looking forward to embarking on the next step of this exciting journey together, bringing cutting edge solutions to the patients and creating impact for society.
